Kyle Richards Dragged Into Weight Loss Drug Use Again After Daughter Laments Going Bald
Kyle Richards has some questions to answer about her daughter Sophia Umansky's experience with weight loss drugs.
The reality star is being blamed for her daughter's indulging in a weight loss remedy after the 25-year-old admitted to the disturbing side effects of it in a TikTok video.
Kyle Richards battled ozempic accusations three years ago after people raised eyebrows over her sudden thin physique on social media.
The actress' daughter shared her distressing experience with hair loss, which she attributes to rapid weight loss rather than the weight-loss medication Mounjaro itself.
In a TikTok video, the 25-year-old revealed that she began noticing significant hair thinning about three weeks to a month after starting the medication four months prior. In her words:
"I started Mounjaro about four months ago, and I would say, like maybe for the past three weeks to a month, I've noticed a dramatic hair loss situation,"
While she currently has a lot of hair, she expressed concern that if the loss continues, she could be bald within a week. Sophia also provided alarming visuals of her hair loss, including clumps of hair found around her shower drain and on the walls, emphasizing that the situation is worse than it appears.
She noted that as she brushes her hair throughout the day, she noted that "piles" often come out. Despite the alarming symptoms, Sophia believes her hair loss stems primarily from the rapid weight loss and nutritional deficiencies associated with it, rather than the medication itself.
She admitted to making a concerted effort to consume more vitamins and protein to address the issue. She has also used OMI hair growth peptides, collagen, and Grüns vitamins to promote health.
While her daughter did not mention Kyle in the video, concerned commenters dragged the doting mother into it, accusing her of setting the trend for the unhealthy practice.
"It's absolutely Kyle's doing- she's very loud about her constant critique of her own appearance and insecurity, and that's definitely rubbed off on her girls," one critic explained, seemingly tying Kyle into the situation. Another person echoed the same sentiment, writing:
"I mean her mom most likely is also on mounjaro.. Women who weren't gym educated, just caloric deficit."
Another asked her why she is on that kind of treatment when she is already "SUPER thin!". One more user explained that Sophia chose mounjaro for the same reason "she got her nose and lips done."
"This is wild. She was never over weight to begin with. Kyle check in on your daughter," a fourth TikTok user declared.
As noted by The Blast in 2023, the "Real Housewives of Beverly Hills" star stood firm against rumors regarding her physique. She insisted that her toned body is the result of hard work and dedication rather than shortcuts.
She shared a series of photos and videos on Instagram under the caption "Life Lately…," including a striking image of herself in a shiny multicolored shirt that revealed a hint of her black lace bra.
However, a gym snapshot showcasing her impressive biceps gained the most attention. In response to allegations about using weight loss drugs like ozempic, she firmly denied the claims, stating, "I have never tried ozempic or any of those medicines, so stop spreading lies. You don't know me."
She emphasized that her muscular physique is a product of her fitness journey, adding, "I have never taken it. I'm not on any weight loss drug." Acknowledging her anxiety, she expressed that such medications would terrify her.
In her Instagram story, she highlighted the difficulty of changing people's beliefs, referring to "motivated reasoning," a psychological notion that explains how individuals cling to their beliefs despite contradicting evidence.
She concluded with a touch of humor, playfully addressing her detractors with a light-hearted remark and the hashtag "#trolls."
In 2023, The Blast shared that the star shared her empowering fitness journey, emphasizing that it was not driven by a desire for revenge after her split from her former partner, Mauricio.
Instead, Kyle highlighted her transformation as a way to focus on her mental and physical well-being. She proudly proclaimed that she was in the best shape of her life, asserting that her new figure was more about feeling good than seeking validation.
She encouraged other women to pursue their fitness goals regardless of age, reflecting on her past and noting that she feels better now than in her 20s and 30s, even after having four children.
The star graced the cover of a magazine to showcase her remarkable results so far, attesting that her journey is truly about self-love and health rather than seeking revenge. Kyle and her estranged husband, Mauricio, announced their separation after 27 years of marriage.
In 2022, a mother of four underwent a significant physical transformation following a breast reduction surgery, which marked a turning point in her life.
After enjoying a vacation in Europe filled with indulgent food and drinks, she returned home feeling unrecognizable and struggling with her mental health, especially after losing her best friend to suicide.
Motivated to make a change, she committed to a strict regimen that eliminated bad carbohydrates, alcohol, and sugar and dedicated herself to daily workouts.
While she had always maintained an exercise routine, she decided to mix it up by incorporating weights, hot yoga, and running to better cope with her emotional challenges. This shift led to noticeable results in her physical fitness.
How will Kyle Richards respond to the new accusations?
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
This Supreme Court Decision Might End Up Displacing Families For Good
High school senior Kyle has visited Chicago three times over the last two years. The 17-year-old has grown to love the Windy City, the birthplace of one of his favorite indie rock bands, Fall Out Boy. He plans to apply to a prestigious arts college there this fall. But the New Orleans teen and his family didn't make these journeys for fun. Chicago was one of the only places where Kyle could continue to access testosterone, part of the gender-affirming care he needed to alleviate his intense feelings of gender dysphoria, after his home state of Louisiana's ban on care went into effect in January 2024. 'I describe it as getting caught up with other boys my age,' Kyle told HuffPost about taking testosterone. He's enjoyed hearing his voice deepen and watching his face become more square. Kyle considers himself lucky as one of the few trans kids in his community that is able to continue accessing care by traveling out of state. He was able to get a $500 grant from the Campaign for Southern Equality, an LGBTQ+ advocacy group, to make the trips more manageable. Without financial resources or family support, the vast majority of his trans friends are instead forced to wait until they're adults to start the process of medically transitioning. HuffPost spoke with three families of transgender youth — all of whom requested to use pseudonyms or to use first names to protect their privacy — who shared stories underscoring the lengths to which they've gone and the distances they've traveled in order to access gender-affirming care for their children in the aftermath of a tidal wave of state-level bans on this care. They may have to continue traveling farther and farther to continue care. Future access to gender-affirming care for transgender youth is now in the hands of the Supreme Court, which is set to issue a ruling this month to decide whether state-level bans on minors are a form of sex discrimination and violate the Constitution. Currently, more than a third of transgender youth age 13 to 17 live across the 26 states that have passed some form of a ban on gender-affirming care, according to a 2024 report from the Williams Institute. The case before the highest court, United States v. Skrmetti, involves Tennessee law SB 1, which bars the use of puberty blockers and hormone treatments for the purpose of gender transition and instead encourages minors to 'appreciate their sex' assigned at birth. The outcome in Skrmetti rests largely on what level of judicial scrutiny, or official skepticism, the justices require Tennessee's law to be examined under. If the court rules that Tennessee has to apply heightened scrutiny — a more rigorous review given to laws around gender discrimination — the state is more likely to lose. In that case, the courts either could flat-out rule the law is unconstitutional, or more possibly, send the case back down to a lower court for reconsideration. If, however, the Court sides with Tennessee and allows for rational basis — a review typically reserved for economic regulations and not classifications of race, gender or national origin — this means that state's ban would remain in effect. Experts worry that could make it more difficult for trans legal advocates to challenge other state bans on gender-affirming care for minors and adults. If the court sides with Tennessee, they say this could open up broader implications for other arenas of legal rights to privacy. Anthony Michael Kreis, a constitutional law professor at Georgia State University, said that Skrmetti is one of several cases on the subject of rights to privacy and bodily autonomy, which have been under attack in recent decades. He thinks about the fight to uphold transgender rights as having separate but overlapping interests with rights to abortion, marriage equality, family formation and parental rights. 'When you start taking that bundle of sticks, that bundle of rights and you remove one and then maybe chop off another, suddenly that entire bundle is a little less stable,' Kreis said. During oral arguments on Tennessee's ban in December, the conservative justices seemed skeptical of trans legal advocates' arguments that SB 1 violates the Constitution. Justice Brett Kavanaugh, who was appointed by President Donald Trump, asked at one point if it was best to leave bans on care up to the 'democratic process,' seemingly suggesting that the issue should be determined by state law — as is now the case with reproductive health care. Many legal experts have begun to imagine what the landscape could look like in the event that the court upholds Tennessee's ban. 'A loss in Skrmetti would give some wind in the sails of conservatives who are trying to chip away at Bostock,' Kreis said, referring to the landmark Supreme Court case which protected employees from discrimination based on sexual orientation or gender identity. In Project 2025, conservative advocates signaled their desire to restrict the application of the 2020 Supreme Court ruling in Bostock to advance transgender rights — and so far at least one conservative Texas judge, Matthew Kacsmaryk, has worked to minimize its impact. The possibility of the Supreme Court upholding Tennessee's ban especially worries families of trans youth within the state. In Nashville, Diane has worked hard to create an affirming childhood for her soon-to-be-14-year-old trans daughter, Lily. She enrolled her in a trans support group, let her pick out her favorite skirts, and has given her space and encouragement as she figures out the kind of girl she wants to be. After Lily told her parents she was trans at age 11, by cc'ing her parents on an email declaring she used she/her pronouns, Diane quickly saw her daughter shed an 'invisible weight.' But in 2022, the state passed its ban on care for trans youth. Many providers in Nashville abruptly stopped seeing patients before the law even went into effect — and later halted care for cisgender youth that could be seen as 'pathways to gender affirmation,' one doctor told HuffPost. Diane's family began to consider out-of-state options within a few hours' driving distance of their home, and landed on a children's hospital in Cincinnati, Ohio. They visited the hospital three times over the course of nine months, speaking with therapists, social workers and doctors. On the last trip, Lily received a hormone blocker insert into her arm to delay the effects of her natal puberty until she turned 14. That same day, Ohio's Republican legislature overturned a veto from Gov. Mike DeWine, banning gender-affirming care for youth in the state. Now the family travels to a clinic in Washington, D.C., where they've been twice already to establish care — and in their next visit this summer, their doctors will work with the family to determine if Lily is ready to start estrogen therapy. Their insurance doesn't cover gender-affirming care and they've exhausted their airline miles. The trips are difficult for Lily, who has to miss school for these appointments, as well as for Diane, who deals with chronic fatigue from long Covid. 'The idea that I'm letting my daughter follow some whim is insulting,' Diane said. 'This is not a whim, this is not a phase — this is who she is.' Other families in the South have even had to consider traveling internationally in order to get gender-affirming care for their children. Ana, a language professor in Birmingham, Alabama, said that she ultimately decided to travel with her son back to her home country of Spain to see a doctor that specializes in gender-affirming care after she tried, and failed, to meet with out-of-state providers that had monthslong waitlists. 'It's like swimming against the current,' Ana said, noting that she hasn't seen her 17-year old-son smile since January. After he first came out as transgender at 13, he was heavily bullied and ostracized by his friends. In Spain, Ana's son (who has dual citizenship) restarted the process of establishing his gender dysphoria diagnosis and a treatment plan from the beginning, even though he had already taken testosterone for three months prior to Alabama's ban. Spain allows trans teens to receive hormone therapy and puberty blockers with support of their parents, and allows anyone over 16 to legally register their gender on documents. Ana said her son plans to move to Europe after graduating high school due to the level of anti-trans legislation and rhetoric in the U.S. 'It feels like he's going to into exile,' she said. Over the last three years, the rising anti-trans legislation in state legislatures coupled with Trump's slate of anti-trans executive orders has dramatically shifted the life decisions of trans youth, their families and even trans adults. Trump has wielded executive orders to threaten to pull federal funding from hospitals that serve LGBTQ+ youth, or schools that allow trans girls to play on female sports teams. Last month, House Republicans passed a massive domestic policy package that would include provisions to bar Medicaid and Affordable Care Act plans from covering gender-affirming care for trans youth and adults alike. The vast uncertainty of the state of transgender rights — as many legal challenges to state and federal actions make their way through the courts — has many families of LGBTQ+ people holding their breath for the Skrmetti decision. But the uncertainty could swing in multiple ways. '[Skmretti] isn't an end-all, be-all. If trans people lose Skrmetti, it's not supposed to be that forever and ever more states can restrict health care for trans youth,' Ezra Young, a New York lawyer and scholar, said. 'The case is very fact-specific. The Supreme Court could say there might be a subset of trans youth for which the state of Tennessee has a special interest in protecting.' Young said the outcome of Skrmetti and the scope of the ruling entirely rests on how the justices write the decision. He likens the significance of a possible victory in Skrmetti to something like Windsor v. U.S., a 2013 case before the Supreme Court that struck down parts of the Defense of Marriage Act, barring gay and lesbian couples from obtaining certain federal tax benefits. The Windsor victory was one case in a chorus of early victories for same-sex marriage — but it wasn't until the court's 2015 Obergefell decision that protected the fundamental right nationwide to same-sex marriage under the Constitution. Similarly, the landscape of trans legal rights and representation has shifted dramatically in the last five years, and often delivered a mixed bag of results. 'It feels like we're left on an island,' said Mariah Moore, the co-director of policy and programs at Transgender Law Center. 'Ever since the Dobbs decision, we're seeing what happens when lifesaving care is no longer available,' she said, referring to the slate of womendying or suffering pregnancy complications after being denied access to abortion-related care in the wake of the Supreme Court's ruling ending the federal right to abortion. When Moore came out as trans in 2006, she remembers how difficult it was to access gender-affirming care, especially without health insurance. 'Black trans women opened their homes for us Black trans kids to eat, be housed, find the right doctor. That's the type of things communities did,' she said. 'I'm a beneficiary of that care and that's what was instilled in generations of queer and trans people.' No matter the outcome this month, Moore said, she knows this isn't the end in the fight for trans liberation. 'Our collective liberation will not come from the courts, the DOJ, DHS, or the Oval Office,' she said. 'That liberation will come when we come together as a people and demand that every single person deserves access to health care.'
Yahoo
7 hours ago
- Yahoo
Domino's Pizza, McDonald's rating surprise tied to persistent consumer issue
Domino's Pizza, McDonald's rating surprise tied to persistent consumer issue originally appeared on TheStreet. Even the Hamburglar didn't see this one coming. Excessive weight has been a persistent problem in America, where at least one in five adults in each U.S. state is living with obesity, according to the Centers for Disease Control and Prevention. 💵💰💰💵 As obesity rates have risen, so have scientists' efforts to address this serious health issue, which can cause asthma, heart disease, stroke, type 2 diabetes and even some cancers. Early attempts to treat obesity came to the market as early as the 1930s. Amphetamines were the prevalent treatment in the 1940s and 1950s and demand continued into the 1990s. Glucagon-like peptide-1 agonists, which mimic the action of the naturally occurring hormone GLP-1, have been available for about two decades. GLP-1 medications, including Ozempic, Wegovy, Zepbound and Mounjaro, have been used for years to treat Type 2 diabetes, and studies have found that they are also effective at encouraging weight loss. Wegovy and Ozempic are manufactured by Novo Nordisk () , while Eli Lilly () makes Zepbound and Mounjaro. One investment firm says increased use of these medications could have serious implications for two of the biggest names in the fast-food industry: McDonald's () and Domino's Pizza () . The market for anti-obesity drugs, particularly those using injectable versions of GLP 1-based drugs, is still new and continuously evolving, Goldman Sachs said in a May 22 report. More Restaurants Beloved Mexican restaurant closing iconic location after 63 years Major restaurant chain quietly closes several locations Iconic restaurant closing its doors after 32 years The investment firm lowered its projections for such medication and now forecasts the global market to reach $95 billion by 2030. That's down from the previous estimate of $130 billion to reflect trends influencing how the drugs are priced, how long patients stay on them, and how patient populations are segmented. Goldman lowered its U.S. market projections to a peak of $70 billion, but the firm sees room for greater penetration in markets outside the U.S. Goldman forecasts a market peak of $50 billion outside the US, compared with $35 billion previously. A survey of more than 50 doctors in the US found that lower doses of anti-obesity medications are working well for a majority of patients and insurance coverage is the most important factor in the decision-making process, Goldman Sachs wrote. 'But to be clear, even with this moderated forecast, we see a significant growth opportunity for both existing players as well as new entrants into this market,' said Asad Haider, head of the health-care business unit within Goldman Sachs Research. Demand for GPL-1 drugs could dramatically hinder the food and restaurant industries, according to a study from Cornell's SC Johnson College of Business and the data firm Numerator. The report, entitled "The No Hunger Games," found that households with at least one user of GLP-1 drugs reduced its grocery spending by about 6% within six months of starting the drugs. The spending cut was as much as 9% for higher-income households. "We also find an 8.6% decline in spending at fast-food chains, coffee shops and limited-service restaurants," the study said. "Our findings highlight the potential for GLP-1 medications to significantly change food demand, a trend with increasingly important implications for the food industry as GLP-1 adoption continues to grow." The study warned that common side effects of GLP-1 medications, such as nausea, vomiting and gastrointestinal discomfort, have reportedly led to reduced adherence or discontinued use for some patients."Moreover, their long-term efficacy and safety remain areas of ongoing investigation," the report said. Redburn Atlantic analyst Chris Luyckx focused on the growing adoption of GLP-1 in recent research reports. Luyckx double-downgraded McDonald's to sell from buy with a price target of $260, down from $319. The analyst expects the GLP-1 weight-loss drugs to suppress consumer appetites and says they present an underappreciated longer-term threat for McDonald's. A 1% drag on sales today "could easily build to 10% or more over time," particularly for restaurant brands skewed toward lower-income consumers, the analyst tells investors in a research note. McDonald's stock was down about 1.3% at last check and is up 18.5% from a year ago. Redburn Atlantic also initiated coverage of Domino's Pizza with a sell rating and $340 price target. Domino's, the world's largest pizza chain, faces the heaviest pressure from adoption of GLP-1 weight loss drugs, with high exposure to dinner occasions and lower-income consumers, the firm said. Redburn Atlantic said the company's organic traffic remains weak, with carry-out far outpacing delivery. Challenged system-sales growth and elevated consensus expectations present downside risk for Domino's, the firm said. McDonald's closed regular trading on June 10 down 1.4% at $300.43. Domino's shares were off 2.7% at $ Pizza, McDonald's rating surprise tied to persistent consumer issue first appeared on TheStreet on Jun 10, 2025 This story was originally reported by TheStreet on Jun 10, 2025, where it first appeared. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11 hours ago
- Yahoo
Can Mounjaro, Zepbound Help Lilly Maintain Dominance in Obesity Space?
Eli Lilly's LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Both have witnessed rapid demand despite being on the market for less than three years. Mounjaro and Zepbound include the same compound tirzepatide, a dual GIP and GLP-1 receptor agonist. Mounjaro and Zepbound generated combined sales of $6.15 billion in the first quarter of 2025, accounting for around 48% of the company's total revenues. Both drugs enjoy increasing market share in the United States. Though sales of Mounjaro and Zepbound were below expectations in the second half of 2024, hurt by slower-than-expected growth and unfavorable channel dynamics, their sales picked up in the first quarter of 2025, driven by launches of the drugs in new international markets and improved supply from ramped-up production. Since 2020, Lilly has committed more than $50 billion to manufacturing capacity for its drugs, mainly Zepbound and Mounjaro, in the United States and Europe. We believe that increased uptake in outside U.S. markets and deeper penetration into the U.S. market will continue to drive Mounjaro and Zepbound's growth in future quarters. Our model estimates combined Mounjaro and Zepbound sales of $48.2 billion by 2027. Approvals for new indications can also drive sales of Mounjaro and Zepbound higher. In late December, the FDA approved Zepbound for its second indication, moderate-to-severe obstructive sleep apnea in adults with obesity. In addition, LLY filed tirzepatide for heart failure, which further expands the opportunity for the candidate. It also expects to announce data from a cardiovascular outcome study on tirzepatide this year. The obesity market is heating up and is expected to expand to $100 billion by 2030, according to data from Goldman Sachs. Lilly and Novo Nordisk NVO presently dominate the market. Mounjaro and Zepbound face strong competition from Novo Nordisk's semaglutide medicines, Ozempic for diabetes and Wegovy for obesity. Several companies like Amgen AMGN and Viking Therapeutics VKTX are also making rapid progress in the development of GLP-1-based candidates in their clinical pipeline. Amgen has begun a broad phase III program on its dual GIPR/GLP-1 receptor agonist, MariTide, across obesity, obesity-related conditions and type II diabetes, with the first two phase III studies initiated in March. Viking Therapeutics' dual GIPR/GLP-1 receptor agonist, VK2735, is being developed both as oral and subcutaneous formulations for the treatment of obesity. Phase III studies with the subcutaneous formulation of VK2735 are on track to begin this year. Others like Roche, Merck and AbbVie are also looking to enter the obesity space by in-licensing obesity candidates from smaller biotechs, which could threaten Novo Nordisk and Eli Lilly's dominance in the market. Lilly's stock has risen 5% so far this year compared with the industry's increase of 0.6%. Image Source: Zacks Investment Research From a valuation standpoint, Lilly's stock is expensive. Going by the price/earnings ratio, the company's shares currently trade at 31.21 forward earnings, higher than 15.17 for the industry. However, the stock is trading below its 5-year mean of 34.54. Image Source: Zacks Investment Research Estimates for Lilly's 2025 earnings have declined from $23.49 to $21.95 per share in the past 60 days, while those for 2026 have declined from $31.28 to $30.91 over the same timeframe. Image Source: Zacks Investment Research Lilly has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report Viking Therapeutics, Inc. (VKTX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
